Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com
A17039 | Pages: 279 | Charts: 63 | Tables: 167 |
The global povidone iodine market size was valued at $152.6 million in 2021, and is projected to reach $242.2 million by 2031, growing at a CAGR of 4.7% from 2022 to 2031. Increase in awareness about hygiene and infection prevention, particularly in the healthcare sector, has driven demand for povidone iodine in wound care, surgical procedures, and personal hygiene products. Povidone iodine is widely used in wound treatment due to its broad-spectrum antimicrobial properties. Its ability to reduce the risk of infections in cuts, abrasions, burns, and other open wounds makes it an essential component of wound care products in hospitals, clinics, and even at home.
Get more information on this report : Request Sample Pages
Povidone, commonly known as polyvinylpyrrolidone (PVP), is primarily used as an antiseptic and disinfectant agent. Povidone's chemical properties such as biological inertness and the ability to bind and form complexes with other materials make it a popular compound in many sectors. Many artificial tear and eye lubricant products contain povidone as a component. Some contact lens manufacturers include povidone as a wetting agent in their lenses to improve moisture retention. Povidone is further utilized as a binder in the manufacture of pharmaceutical tablets and liquid oral medications. Moreover, it is frequently found in cosmetic products such as shampoos, lipstick, hair spray, and gels.
Povidone iodine can minimize the irritating or poisonous properties of other medications. it is frequently mixed with iodine as an antiseptic. This combination product is sold as Betadine®, a skin antiseptic, but it is also available in lower concentrations for treatment of the eyes and vaginal area. In addition, povidone iodine is commonly used as an antiseptic in surgical operations in hospitals. For healthcare professionals, nose and oral cleansing with povidone iodine has recently been recommended as a COVID-19 infection prevention intervention. As the effectiveness of this medication is unknown, using povidone iodine to prevent COVID-19 is still considered experimental.
The antibacterial properties of povidone iodine enable it to kill bacteria, viruses, and fungus. As a disinfectant, povidone iodine is becoming increasingly popular in the healthcare sector. Antiseptic product demand is rising as invasive procedures become more common and the healthcare business expands rapidly in both developed and developing nations. In addition, rise in prevalence of numerous diseases in hospitals and clinics has boosted the demand for instrument sterilizers, boosting the demand for povidone iodine.
Key Takeaways
The povidone iodine market study covers 20 countries. The research includes a segment analysis of each country in terms of value for the projected period.
The study integrated high-quality data, professional opinions and analysis, and critical independent perspectives. The research approach is intended to provide a balanced view of the global povidone iodine market and to assist stakeholders in making educated decisions in order to achieve their most ambitious growth objectives.
Over 3,700 product literatures, annual reports, industry statements, and other comparable materials from major industry participants were reviewed to gain a better understanding of the povidone iodine market.
The povidone iodine market is highly fragmented, with several players including 3M Company, Avrio Health L.P., BASF SE, Glide Chem Private Limited, Lasa Supergenerics Ltd., Luxica Pharma Inc, NIPPON SHOKUBAI CO., LTD., Samrat Pharmachem Limited, Thatcher Company, and Vishal Laboratories. Key strategies such as acquisitions, product launches, mergers, expansion etc. of the players operating in the povidone iodine market are also included in the report.
Rise in chronic diseases, such as diabetes, cancer, and cardiovascular conditions and associated surgeries is expected to drive the growth of the povidone iodine market during the forecast period. Chronic conditions often require regular medical interventions, including surgeries, to manage complications or improve patient outcomes. For instance, diabetes can lead to non-healing wounds or ulcers that often necessitate surgical treatment. In such cases, povidone iodine is widely used in wound care to prevent infections, which is critical for diabetic patients who are more prone to infections due to their compromised immune systems.
Similarly, cancer treatments frequently involve surgical procedures to remove tumors or manage complications associated with the disease. Patients undergoing cancer surgery are at high risk of postoperative infections due to weakened immune systems from chemotherapy or radiation. Here, povidone iodine serves as a reliable antiseptic agent in both preoperative and postoperative care, helping reduce the risk of infections and promoting better recovery outcomes. Cardiovascular surgeries, such as bypasses or valve replacements, also rely heavily on antiseptics like povidone iodine to maintain sterile environments and minimize the chances of infections during and after surgery. According to Dr. O'Brien, the continued use of 2.5% povidone-iodine could be considered a best practice, not only for combatting SARS-CoV-2 but also for preventing the spread of other transmissible viruses such as adenovirus, enterovirus, influenza, and certain bacteria.
However, the availability of alternative antiseptics is expected to restrain the growth of the povidone iodine market during the forecast period. The availability of alternative antiseptics presents a significant restraint on the growth of the povidone iodine industry. Products such as chlorhexidine, hydrogen peroxide, and alcohol-based solutions are widely used across various healthcare settings and often compete directly with povidone iodine. These alternatives offer similar antimicrobial properties, making them viable substitutes in preventing and treating infections. In many cases, chlorhexidine and alcohol-based products are preferred due to their rapid action, ease of use, and lower incidence of skin irritation compared to povidone iodine. This has led to their increased adoption, especially in clinical and surgical environments. In addition, some of these alternatives are associated with fewer side effects, which further enhances their appeal. For instance, povidone iodine is known to cause skin discoloration and, in some individuals, allergic reactions or sensitivity issues, limiting its use in specific patient groups. In contrast, alcohol-based antiseptics evaporate quickly, leaving no residue, and are less likely to cause skin staining. Chlorhexidine, on the other hand, offers prolonged antimicrobial activity, making it especially useful for longer-term infection prevention in surgical procedures, reducing the need for reapplication.
The povidone iodine market is segmented on the basis of formulation type, application, and region. Depending on formulation type, the market is categorized into scrub, topical solution, ointments, and others (powder and gel). By application, it is segregated into skin sterilization, instrument sterilization, disinfectant, and others. Region wise, it is studied across North America, Europe, Asia-Pacific, and LAMEA.
[FORMULATIONTYPEGRAPH]
Get more information on this report : Request Sample Pages
By type, the topical solution segment dominated the povidone iodine market share in 2021 and is expected to grow with the CAGR of 4.9% during the forecast period. Povidone-iodine, commonly known as a topical antiseptic, is widely used to prevent and treat skin infections in wounds, cuts, and burns. As a combination of iodine and a water-soluble polymer, polyvinylpyrrolidone (PVP), povidone-iodine has potent antimicrobial properties, effective against a broad spectrum of bacteria, viruses, fungi, and protozoa. Its use as a topical solution makes it ideal for disinfecting skin before surgeries and other medical procedures, reducing the risk of post-operative infections.
[APPLICATIONGRAPH]
Get more information on this report : Request Sample Pages
By application, the disinfectant segment dominated the povidone iodine market, with a CAGR of 5.1% during the forecast period. Povidone-iodine is a widely used antiseptic and disinfectant due to its broad-spectrum antimicrobial properties. It is an iodine-based solution that works by releasing free iodine when applied to the skin or mucous membranes, which disrupts the vital components of microorganisms such as bacteria, viruses, fungi, and protozoa. Its ability to act against a wide variety of pathogens makes it a valuable tool in both healthcare and household settings for preventing infections and maintaining cleanliness.
[REGIONGRAPH]
Get more information on this report : Request Sample Pages
Region-wise, Europe accounted for the largest share of the market in 2021, and Asia-Pacific is expected to grow with a CAGR of 5.3% during the forecast period. Povidone-iodine, a broad-spectrum antiseptic, is widely used across Europe for various applications due to its effective antimicrobial properties. It is primarily utilized in healthcare settings for preoperative skin disinfection, wound care, and as a surgical scrub for healthcare professionals. In the UK, povidone-iodine is a commonly used antiseptic in hospitals and clinics. It is primarily applied for preoperative skin preparation and wound care. The National Health Service (NHS) endorses its use due to its effectiveness in reducing the risk of surgical infections. In addition, povidone-iodine is available in retail pharmacies for treating minor injuries and infections, highlighting its accessibility for consumers.
Major players operating in the global povidone iodine market include 3M Company, Avrio Health L.P., BASF SE, Glide Chem Private Limited, Lasa Supergenerics Ltd., Luxica Pharma Inc, NIPPON SHOKUBAI CO., LTD., Samrat Pharmachem Limited, Thatcher Company, and Vishal Laboratories. Other players operating in the povidone iodine industry are Evonik Industries AG, LG Chem Ltd., Sumitomo Seika Chemicals Co. Ltd., Sanyo Chemical Industries, and KAO Corporation.
In 1952, povidone-iodine was first marketed under the brand name Betadine by the company Medi-chem, which was later acquired by Purdue Pharma. The formulation combines iodine with povidone (polyvinylpyrrolidone) to create a less irritating antiseptic.
In 1960, povidone-iodine gained significant attention as a surgical antiseptic. Its use in hospitals began to expand rapidly, becoming a standard practice in preoperative and postoperative care.
In 1990, povidone-iodine was studied extensively for its efficacy in preventing surgical site infections, particularly in orthopedic and cardiovascular surgeries.
In 2000, povidone-iodine was included in various guidelines by health organizations for infection control, particularly in surgical settings and wound management.
In 2008, the World Health Organization (WHO) recognized povidone-iodine as a critical antiseptic for hand hygiene and preoperative skin preparation.
KEY BENEFITS FOR STAKEHOLDERS
Key Market Segments
Key Market Players
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology
1.4.1.Primary research
1.4.2.Secondary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.Key findings
2.2.1.Top investment pockets
2.3.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key forces shaping the povidone iodine market
3.2.1.Bargaining power of the suppliers
3.2.2.Bargaining power of the buyers
3.2.3.Threat of new entrants
3.2.4.Threat of substitutes
3.2.5.Competitive rivalry
3.3.Market dynamics
3.3.1.Drivers
3.3.1.1.Increased demand from pharmaceutical industry
3.3.1.2.Surge in demand for antiseptic creams
3.3.2.Restraint
3.3.2.1.Side effects associated with the usage of povidone iodine
3.3.3.Opportunity
3.3.3.1.Increase in demand from emerging economies
3.4.Value chain
3.5.Pricing analysis
3.6.Patent analysis, 2014–2021
3.7.Impact of COVID-19 outbreak on the povidone iodine market
CHAPTER 4:POVIDONE IODINE MARKET, BY FORMULATION TYPE
4.1.Overview
4.1.1.Market size and forecast
4.2.Scrub
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.3.Topical solution
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country
4.4.Ointments
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country
4.5.Others (powder and gel)
4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country
CHAPTER 5:POVIDONE IODINE MARKET, BY APPLICATION
5.1.Overview
5.1.1.Market size and forecast
5.2.Skin sterilization
5.2.1.Key market trends, growth factors, and opportunities
5.2.2.Market size and forecast, by region
5.2.3.Market analysis, by country
5.3.Instrument sterilization
5.3.1.Key market trends, growth factors, and opportunities
5.3.2.Market size and forecast, by region
5.3.3.Market analysis, by country
5.4.Disinfectant
5.4.1.Key market trends, growth factors, and opportunities
5.4.2.Market size and forecast, by region
5.4.3.Market analysis, by country
5.5.Others
5.5.1.Key market trends, growth factors, and opportunities
5.5.2.Market size and forecast, by region
5.5.3.Market analysis, by country
CHAPTER 6:POVIDONE IODINE MARKET, BY REGION
6.1.Overview
6.1.1.Market size and forecast
6.2.North America
6.2.1.Key market trends, growth factors, and opportunities
6.2.2. Market size and forecast, by formulation type
6.2.3.Market size and forecast, by application
6.2.4.Market share analysis, by country
6.2.4.1.U.S.
6.2.4.1.1.Market size and forecast, by formulation type
6.2.4.1.2.Market size and forecast, by application
6.2.4.2.Canada
6.2.4.2.1.Market size and forecast, by formulation type
6.2.4.2.2.Market size and forecast, by application
6.2.4.3.Mexico
6.2.4.3.1.Market size and forecast, by formulation type
6.2.4.3.2.Market size and forecast, by application
6.3.Europe
6.3.1.Key market trends, growth factors, and opportunities
6.3.2.Market size and forecast, by formulation type
6.3.3.Market size and forecast, by application
6.3.4.Market share analysis, by country
6.3.4.1.Germany
6.3.4.1.1.Market size and forecast, by formulation type
6.3.4.1.2.Market size and forecast, by application
6.3.4.2.France
6.3.4.2.1.Market size and forecast, by formulation type
6.3.4.2.2.Market size and forecast, by application
6.3.4.3.Belgium
6.3.4.3.1.Market size and forecast, by formulation type
6.3.4.3.2.Market size and forecast, by application
6.3.4.4.Italy
6.3.4.4.1.Market size and forecast, by formulation type
6.3.4.4.2.Market size and forecast, by application
6.3.4.5.Netherlands
6.3.4.5.1.Market size and forecast, by formulation type
6.3.4.5.2.Market size and forecast, by application
6.3.4.6.Rest of Europe
6.3.4.6.1.Market size and forecast, by formulation type
6.3.4.6.2.Market size and forecast, by application
6.4.Asia-Pacific
6.4.1.Key market trends, growth factors, and opportunities
6.4.2.Market size and forecast, by formulation type
6.4.3.Market size and forecast, by application
6.4.4.Market share analysis, by country
6.4.4.1.China
6.4.4.1.1.Market size and forecast, by formulation type
6.4.4.1.2.Market size and forecast, by application
6.4.4.2.Japan
6.4.4.2.1.Market size and forecast, by formulation type
6.4.4.2.2.Market size and forecast, by application
6.4.4.3.India
6.4.4.3.1.Market size and forecast, by formulation type
6.4.4.3.2.Market size and forecast, by application
6.4.4.4.South Korea
6.4.4.4.1.Market size and forecast, by formulation type
6.4.4.4.2.Market size and forecast, by application
6.4.4.5.Australia
6.4.4.5.1.Market size and forecast, by formulation type
6.4.4.5.2.Market size and forecast, by application
6.4.4.6.Rest of Asia-Pacific
6.4.4.6.1.Market size and forecast, by formulation type
6.4.4.6.2.Market size and forecast, by application
6.5.LAMEA
6.5.1.Key market trends, growth factors, and opportunities
6.5.2.Market size and forecast, by formulation type
6.5.3.Market size and forecast, by application
6.5.4.Market share analysis, by country
6.5.4.1.Brazil
6.5.4.1.1.Market size and forecast, by formulation type
6.5.4.1.2.Market size and forecast, by application
6.5.4.2.UAE
6.5.4.2.1.Market size and forecast, by formulation type
6.5.4.2.2.Market size and forecast, by application
6.5.4.3.Saudi Arabia
6.5.4.3.1.Market size and forecast, by formulation type
6.5.4.3.2.Market size and forecast, by application
6.5.4.4.South Africa
6.5.4.4.1.Market size and forecast, by formulation type
6.5.4.4.2.Market size and forecast, by application
6.5.4.5.Rest of LAMEA
6.5.4.5.1.Market size and forecast, by formulation type
6.5.4.5.2.Market size and forecast, by application
CHAPTER 7:COMPETITIVE LANDSCAPE
7.1.INTRODUCTION
7.1.1.MARKET PLAYER POSITIONING, 2021
7.2.TOP WINNING STRATEGIES
7.2.1.Top winning strategies, by year
7.2.2.Top winning strategies, by development
7.2.3.Top winning strategies, by company
7.3.PRODUCT MAPPING OF TOP 10 PLAYERS
7.4.COMPETITIVE HEATMAP
7.5.KEY DEVELOPMENTS
7.5.1.New product launches
7.5.2.Acquisition
CHAPTER 8:COMPANY PROFILES:
8.1.Avrio Health L.P.
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Product portfolio
8.1.4.Key strategic moves and developments
8.2.BASF SE
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Business performance
8.3.Glide Chem Private Limited
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Product portfolio
8.4.Lasa Supergenerics Ltd.
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Product portfolio
8.4.4.Business performance
8.4.5.Key strategic moves and developments
8.5.Luxica Pharma Inc.
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Product portfolio
8.6.Nippon Shokubai Co Ltd.
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance
8.7.Samrat Pharmachem Limited
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Product portfolio
8.7.4.Business performance
8.8.Thatcher Company
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Product portfolio
8.9.Vishal Laboratories
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Product portfolio
8.10.3M Company
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance
LIST OF TABLES
TABLE 01.GLOBAL POVIDONE IODINE MARKET, BY FORMULATION TYPE, 2021-2031(TON)
TABLE 02.GLOBAL POVIDONE IODINE MARKET, BY FORMULATION TYPE, 2021-2031($THOUSAND)
TABLE 03.POVIDONE IODINE SCRUB MARKET, BY REGION, 2021-2031(TON)
TABLE 04.POVIDONE IODINE SCRUB MARKET, BY REGION, 2021-2031($THOUSAND)
TABLE 05.POVIDONE IODINE TOPICAL SOLUTION MARKET, BY REGION, 2021-2031(TON)
TABLE 06.POVIDONE IODINE TOPICAL SOLUTION MARKET, BY REGION, 2021-2031($THOUSAND)
TABLE 07.POVIDONE IODINE OINTMENTS MARKET, BY REGION, 2021-2031(TON)
TABLE 08.POVIDONE IODINE OINTMENTS MARKET, BY REGION, 2021-2031($THOUSAND)
TABLE 09.POVIDONE IODINE MARKET FOR OTHER FORMULATION TYPE, BY REGION, 2021-2031(TON)
TABLE 10.POVIDONE IODINE MARKET FOR OTHER FORMULATION TYPE, BY REGION, 2021-2031($THOUSAND)
TABLE 11.GLOBAL POVIDONE IODINE MARKET, BY APPLICATION, 2021-2031(TON)
TABLE 12.GLOBAL POVIDONE IODINE MARKET, BY APPLICATION, 2021-2031(THOUSAND)
TABLE 13.POVIDONE IODINE MARKET FOR SKIN STERILIZATION, BY REGION, 2021-2031(TON)
TABLE 14.POVIDONE IODINE MARKET FOR SKIN STERILIZATION, BY REGION, 2021-2031($THOUSAND)
TABLE 15.POVIDONE IODINE MARKET FOR INSTRUMENT STERILIZATION, BY REGION, 2021-2031(TON)
TABLE 16.POVIDONE IODINE MARKET FOR INSTRUMENT STERILIZATION, BY REGION, 2021-2031($THOUSAND)
TABLE 17.POVIDONE IODINE MARKET FOR DISINFECTANT, BY REGION, 2021-2031(TON)
TABLE 18.POVIDONE IODINE MARKET FOR DISINFECTANT, BY REGION, 2021-2031($THOUSAND)
TABLE 19.POVIDONE IODINE MARKET FOR OTHER APPLICATION, BY REGION, 2021-2031(TON)
TABLE 20.POVIDONE IODINE MARKET FOR OTHER END USE INDUSTRY, BY REGION, 2021-2031($THOUSAND)
TABLE 21.POVIDONE IODINE MARKET, BY REGION, 2021-2031(TON)
TABLE 22.POVIDONE IODINE MARKET, BY REGION, 2021-2031($THOUSAND)
TABLE 23.NORTH AMERICA POVIDONE IODINE MARKET, BY FORMULATION TYPE, 2021-2031(TON)
TABLE 24.NORTH AMERICA POVIDONE IODINE MARKET, BY FORMULATION TYPE, 2021-2031($THOUSAND)
TABLE 25.NORTH AMERICA POVIDONE IODINE MARKET, BY APPLICATION, 2021-2031(TON)
TABLE 26.NORTH AMERICA POVIDONE IODINE MARKET, BY APPLICATION, 2021-2031($THOUSAND)
TABLE 27.NORTH AMERICA POVIDONE IODINE MARKET, BY COUNTRY, 2021-2031(TON)
TABLE 28.NORTH AMERICA POVIDONE IODINE MARKET, BY COUNTRY, 2021-2031($THOUSAND)
TABLE 29.U.S. POVIDONE IODINE MARKET, BY FORMULATION TYPE, 2021-2031(TON)
TABLE 30.U.S. POVIDONE IODINE MARKET, FORMULATION TYPE, 2021-2031($THOUSAND)
TABLE 31.U.S. POVIDONE IODINE MARKET, BY APPLICATION, 2021-2031(TON)
TABLE 32.U.S. POVIDONE IODINE MARKET, BY APPLICATION, 2021-2031($THOUSAND)
TABLE 33.CANADA POVIDONE IODINE MARKET, BY FORMULATION TYPE, 2021-2031(TON)
TABLE 34.CANADA POVIDONE IODINE MARKET, BY FORMULATION TYPE, 2021-2031($THOUSAND)
TABLE 35.CANADA POVIDONE IODINE MARKET, BY APPLICATION, 2021-2031(TON)
TABLE 36.CANADA POVIDONE IODINE MARKET, BY APPLICATION, 2021-2031($THOUSAND)
TABLE 37.MEXICO POVIDONE IODINE MARKET, BY FORMULATION TYPE, 2021-2031(TON)
TABLE 38.MEXICO POVIDONE IODINE MARKET, BY FORMULATION TYPE, 2021-2031($THOUSAND)
TABLE 39.MEXICO POVIDONE IODINE MARKET, BY APPLICATION, 2021-2031(TON)
TABLE 40.MEXICO POVIDONE IODINE MARKET, BY APPLICATION, 2021-2031($THOUSAND)
TABLE 41.EUROPE POVIDONE IODINE MARKET, BY FORMULATION TYPE, 2021-2031(TON)
TABLE 42.EUROPE POVIDONE IODINE MARKET, BY FORMULATION TYPE, 2021-2031($THOUSAND)
TABLE 43.EUROPE POVIDONE IODINE MARKET, BY APPLICATION, 2021-2031(TON)
TABLE 44.EUROPE POVIDONE IODINE MARKET, BY APPLICATION, 2021-2031($THOUSAND)
TABLE 45.EUROPE POVIDONE IODINE MARKET, BY COUNTRY, 2021-2031(TON)
TABLE 46.EUROPE POVIDONE IODINE MARKET, BY COUNTRY, 2021-2031($THOUSAND)
TABLE 47.GERMANY POVIDONE IODINE MARKET, BY FORMULATION TYPE, 2021-2031(TON)
TABLE 48.GERMANY POVIDONE IODINE MARKET, BY FORMULATION TYPE, 2021-2031($THOUSAND)
TABLE 49.GERMANY POVIDONE IODINE MARKET, BY APPLICATION, 2021-2031(TON)
TABLE 50.GERMANY POVIDONE IODINE MARKET, BY APPLICATION, 2021-2031($THOUSAND)
TABLE 51.FRANCE POVIDONE IODINE MARKET, BY FORMULATION TYPE, 2021-2031(TON)
TABLE 52.FRANCE POVIDONE IODINE MARKET, BY FORMULATION TYPE, 2021-2031($THOUSAND)
TABLE 53.FRANCE POVIDONE IODINE MARKET, BY APPLICATION, 2021-2031(TON
TABLE 55.FRANCE POVIDONE IODINE MARKET, BY APPLICATION, 2021-2031($THOUSAND)
TABLE 56.BELGIUM POVIDONE IODINE MARKET, BY FORMULATION TYPE, 2021-2031(TON)
TABLE 57.BELGIUM POVIDONE IODINE MARKET, BY FORMULATION TYPE, 2021-2031($THOUSAND)
TABLE 58.BELGIUM POVIDONE IODINE MARKET, BY APPLICATION, 2021-2031(TON)
TABLE 60.BELGIUM POVIDONE IODINE MARKET, BY APPLICATION, 2021-2031($THOUSAND)
TABLE 61.ITALY POVIDONE IODINE MARKET, BY FORMULATION TYPE, 2021-2031(TON)
TABLE 62.ITALY POVIDONE IODINE MARKET, BY FORMULATION TYPE, 2021-2031($THOUSAND)
TABLE 63.ITALY POVIDONE IODINE MARKET, BY APPLICATION, 2021-2031(TON)
TABLE 65.ITALY POVIDONE IODINE MARKET, BY APPLICATION, 2021-2031($THOUSAND)
TABLE 66.NETHERLANDS POVIDONE IODINE MARKET, BY FORMULATION TYPE, 2021-2031(TON)
TABLE 67.NETHERLANDS POVIDONE IODINE MARKET, BY FORMULATION TYPE ($THOUSAND)
TABLE 68.NETHERLANDS POVIDONE IODINE MARKET, BY APPLICATION, 2021-2031(TON)
TABLE 69.NETHERLANDS POVIDONE IODINE MARKET, BY APPLICATION, 2021-2031($THOUSAND)
TABLE 70.REST OF EUROPE POVIDONE IODINE MARKET, BY FORMULATION TYPE, 2021-2031(TON)
TABLE 71.REST OF EUROPE POVIDONE IODINE MARKET, BY FORMULATION TYPE, 2021-2031($THOUSAND)
TABLE 72.REST OF EUROPE POVIDONE IODINE MARKET, BY APPLICATION, 2021-2031(TON)
TABLE 73.REST OF EUROPE POVIDONE IODINE MARKET, BY APPLICATION, 2021-2031($THOUSAND)
TABLE 74.ASIA-PACIFIC POVIDONE IODINE MARKET, BY FORMULATION TYPE, 2021-2031(TON)
TABLE 75.ASIA-PACIFIC POVIDONE IODINE MARKET, BY FORMULATION TYPE, 2021-2031($THOUSAND)
TABLE 76.ASIA-PACIFIC POVIDONE IODINE MARKET, BY APPLICATION, 2021-2031(TON)
TABLE 77.ASIA-PACIFIC POVIDONE IODINE MARKET, BY APPLICATION, 2021-2031($THOUSAND)
TABLE 78.ASIA-PACIFIC POVIDONE IODINE MARKET, BY COUNTRY, 2021-2031(TON)
TABLE 79.ASIA-PACIFIC POVIDONE IODINE MARKET, BY COUNTRY, 2021-2031($THOUSAND)
TABLE 80.CHINA POVIDONE IODINE MARKET, BY FORMULATION TYPE, 2021-2031(TON)
TABLE 81.CHINA POVIDONE IODINE MARKET, BY FORMULATION TYPE, 2021-2031($THOUSAND)
TABLE 82.CHINA POVIDONE IODINE MARKET, BY APPLICATION, 2021-2031(TON)
TABLE 84.CHINA POVIDONE IODINE MARKET, BY APPLICATION, 2021-2031($THOUSAND)
TABLE 85.JAPAN POVIDONE IODINE MARKET, BY FORMULATION TYPE, 2021-2031(TON)
TABLE 86.JAPAN POVIDONE IODINE MARKET, BY FORMULATION TYPE, 2021-2031($THOUSAND)
TABLE 87.JAPAN POVIDONE IODINE MARKET, BY APPLICATION, 2021-2031(TON)
TABLE 89.JAPAN POVIDONE IODINE MARKET, BY APPLICATION, 2021-2031($THOUSAND)
TABLE 90.INDIA POVIDONE IODINE MARKET, BY FORMULATION TYPE, 2021-2031(TON)
TABLE 91.INDIA POVIDONE IODINE MARKET, BY FORMULATION TYPE, 2021-2031($THOUSAND)
TABLE 92.INDIA POVIDONE IODINE MARKET, BY APPLICATION, 2021-2031(TON)
TABLE 94.INDIA POVIDONE IODINE MARKET, BY APPLICATION, 2021-2031($THOUSAND)
TABLE 95.SOUTH KOREA POVIDONE IODINE MARKET, BY FORMULATION TYPE, 2021-2031(TON)
TABLE 96.SOUTH KOREA POVIDONE IODINE MARKET, BY FORMULATION TYPE, 2021-2031($THOUSAND)
TABLE 97.SOUTH KOREA POVIDONE IODINE MARKET, BY APPLICATION, 2021-2031(TON)
TABLE 99.SOUTH KOREA POVIDONE IODINE MARKET, BY APPLICATION, 2021-2031($THOUSAND)
TABLE 100.AUSTRALIA POVIDONE IODINE MARKET, BY FORMULATION TYPE, 2021-2031(TON)
TABLE 101.AUSTRALIA POVIDONE IODINE MARKET, BY FORMULATION TYPE, 2021-2031($THOUSAND)
TABLE 102.AUSTRALIA POVIDONE IODINE MARKET, BY APPLICATION, 2021-2031(TON)
TABLE 104.AUSTRALIA POVIDONE IODINE MARKET, BY APPLICATION, 2021-2031($THOUSAND)
TABLE 105.REST OF ASIA-PACIFIC POVIDONE IODINE MARKET, BY FORMULATION TYPE, 2021-2031(TON)
TABLE 106.REST OF ASIA-PACIFIC POVIDONE IODINE MARKET, BY FORMULATION TYPE, 2021-2031($THOUSAND)
TABLE 107.REST OF ASIA-PACIFIC POVIDONE IODINE MARKET, BY APPLICATION, 2021-2031(TON)
TABLE 109.REST OF ASIA-PACIFIC POVIDONE IODINE MARKET, BY APPLICATION, 2021-2031($THOUSAND)
TABLE 110.LAMEA POVIDONE IODINE MARKET, BY FORMULATION TYPE, 2021-2031(TON)
TABLE 111.LAMEA POVIDONE IODINE MARKET, BY FORMULATION TYPE, 2021-2031($THOUSAND)
TABLE 112.LAMEA POVIDONE IODINE MARKET, BY APPLICATION, 2021-2031(TON)
TABLE 113.LAMEA POVIDONE IODINE MARKET, BY FORMULATION TYPE, 2021-2031($THOUSAND)
TABLE 114.LAMEA POVIDONE IODINE MARKET, BY COUNTRY, 2021-2031(TON)
TABLE 115.LAMEA POVIDONE IODINE MARKET, BY COUNTRY, 2021-2031($THOUSAND)
TABLE 116.BRAZIL POVIDONE IODINE MARKET, BY FORMULATION TYPE, 2021-2031(TON)
TABLE 117.BRAZIL POVIDONE IODINE MARKET, BY FORMULATION TYPE, 2021-2031($THOUSAND)
TABLE 118.BRAZIL POVIDONE IODINE MARKET, BY APPLICATION, 2021-2031(TON)
TABLE 119.BRAZIL POVIDONE IODINE MARKET, BY APPLICATION, 2021-2031($THOUSAND)
TABLE 120.UAE POVIDONE IODINE MARKET, BY FORMULATION TYPE, 2021-2031(TON)
TABLE 121.UAE POVIDONE IODINE MARKET, BY FORMULATION TYPE, 2021-2031($THOUSAND)
TABLE 122.UAE POVIDONE IODINE MARKET, BY APPLICATION, 2021-2031(TON)
TABLE 123.UAE POVIDONE IODINE MARKET, BY APPLICATION, 2021-2031($THOUSAND)
TABLE 124.SAUDI ARABIA POVIDONE IODINE MARKET, BY FORMULATION TYPE, 2021-2031(TON)
TABLE 125.SAUDI ARABIA POVIDONE IODINE MARKET, BY FORMULATION TYPE, 2021-2031($THOUSAND)
TABLE 126.SAUDI ARABIA POVIDONE IODINE MARKET, BY APPLICATION, 2021-2031(TON)
TABLE 127.SAUDI ARABIA POVIDONE IODINE MARKET, BY APPLICATION, 2021-2031($THOUSAND)
TABLE 128.SOUTH AFRICA POVIDONE IODINE MARKET, BY FORMULATION TYPE, 2021-2031(TON)
TABLE 129.SOUTH AFRICA POVIDONE IODINE MARKET, BY FORMULATION TYPE, 2021-2031($THOUSAND)
TABLE 130.SOUTH AFRICA POVIDONE IODINE MARKET, BY APPLICATION, 2021-2031(TON)
TABLE 131.SOUTH AFRICA POVIDONE IODINE MARKET, BY APPLICATION, 2021-2031($THOUSAND)
TABLE 132.REST OF LAMEA POVIDONE IODINE MARKET, BY FORMULATION TYPE, 2021-2031(TON)
TABLE 133.REST OF LAMEA POVIDONE IODINE MARKET, BY FORMULATION TYPE, 2021-2031($THOUSAND)
TABLE 134.REST OF LAMEA POVIDONE IODINE MARKET, BY APPLICATION, 2021-2031(TON)
TABLE 135.REST OF LAMEA POVIDONE IODINE MARKET, BY APPLICATION, 2021-2031($THOUSAND)
TABLE 136.KEY NEW PRODUCT LAUNCH (2020-2021)
TABLE 137.KEY ACQUISITION (2020-2021)
TABLE 138.AVRIO: COMPANY SNAPSHOT
TABLE 139.AVRIO: PRODUCT PORTFOLIO
TABLE 140.AVRIO: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 141.BASF SE: COMPANY SNAPSHOT
TABLE 142.BASF SE: OPERATING SEGMENTS
TABLE 143.BASF: PRODUCT PORTFOLIO
TABLE 144.BASF SE: NET SALES, 2019–2021 ($MILLION)
TABLE 145.GLIDE: COMPANY SNAPSHOT
TABLE 146.GLIDE: PRODUCT PORTFOLIO
TABLE 147.LASA: COMPANY SNAPSHOT
TABLE 148.LASA: PRODUCT PORTFOLIO
TABLE 149.LASA: NET SALES, 2018–2020 ($MILLION)
TABLE 150.LASA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 151.LUXICA: COMPANY SNAPSHOT
TABLE 152.LUXICA: PRODUCT PORTFOLIO
TABLE 153.NIPPON SHOKUBAI: COMPANY SNAPSHOT
TABLE 154.NIPPON SHOKUBAI: OPERATING SEGMENT
TABLE 155.NIPPON SHOKUBAI: PRODUCT PORTFOLIO
TABLE 156.NIPPON SHOKUBAI: NET SALES, 2019–2021 ($MILLION)
TABLE 157.SAMRAT: COMPANY SNAPSHOT
TABLE 158.SAMRAT: PRODUCT PORTFOLIO
TABLE 159.SAMRAT: NET SALES, 2018–2020 ($MILLION)
TABLE 160.THATCHER: COMPANY SNAPSHOT
TABLE 161.THATCHER: PRODUCT PORTFOLIO
TABLE 162.VISHAL LABORATORIES: COMPANY SNAPSHOT
TABLE 163.VISHAL LABORATORIES: PRODUCT PORTFOLIO
TABLE 164.3M: COMPANY SNAPSHOT
TABLE 165.3M: OPERATING SEGMENTS
TABLE 166.3M: PRODUCT PORTFOLIO
TABLE 167.3M: NET SALES, 2019–2021 ($MILLION)
LIST OF FIGURES
FIGURE 01.KEY MARKET SEGMENTS
FIGURE 02.GLOBAL POVIDONE IODINE MARKET SNAPSHOT, BY SEGMENTION, 2021-2031
FIGURE 03.POVIDONE IODINE MARKETSNAPSHOT, BY REGION, 2022-2031
FIGURE 04.TOP INVESTMENT POCKETS, BY COUNTRY
FIGURE 05.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 06.HIGH BARGAINING POWER OF BUYERS
FIGURE 07.MODERATE THREAT OF NEW ENTRANTS
FIGURE 08.MODERATE THREAT OF SUBSTITUTES
FIGURE 09.MODERATE INTENSITY OF RIVALRY
FIGURE 10.GLOBAL POVIDONE IODINE MARKET DYNAMICS
FIGURE 11.GLOBAL POVIDONE IODINE MARKET: VALUE CHAIN
FIGURE 12.PRICING ANALYSIS, BY REGION
FIGURE 13.PATENT ANALYSIS, BY COUNTRY
FIGURE 14.PATENT ANALYSIS, BY APPLICANT
FIGURE 15.PATENT ANALYSIS, BY INVENTOR
FIGURE 16.GLOBAL POVIDONE IODINE MARKET, BY FORMULATION TYPE, 2021–2031 ($THOUSAND)
FIGURE 17.COMPARATIVE ANALYSIS OF POVIDONE IODINE SCRUB MARKET, BY COUNTRY, 2021 & 2031 ($THOUSAND)
FIGURE 18.COMPARATIVE ANALYSIS OF POVIDONE IODINE TOPICAL SOLUTION MARKET, BY COUNTRY, 2021 & 2031 ($THOUSAND)
FIGURE 19.COMPARATIVE ANALYSIS OF POVIDONE IODINE OINTMENTS MARKET, BY COUNTRY, 2021 & 2031 ($THOUSAND)
FIGURE 20.COMPARATIVE ANALYSIS OF POVIDONE IODINE MARKET FOR OTHER FORMULATION TYPE, BY COUNTRY, 2021 & 2031 ($THOUSAND)
FIGURE 21.GLOBAL POVIDONE IODINE MARKET, BY APPLICATION, 2021–2031 ($THOUSAND)
FIGURE 22.COMPARATIVE ANALYSIS OF POVIDONE IODINE MARKET FOR SKIN STERILIZATION, BY COUNTRY, 2021 & 2031 ($THOUSAND)
FIGURE 23.COMPARATIVE ANALYSIS OF POVIDONE IODINE MARKET FOR INSTRUMENT STERILIZATION, BY COUNTRY, 2021 & 2031 ($THOUSAND)
FIGURE 24.COMPARATIVE ANALYSIS OF POVIDONE IODINE MARKET FOR DISINFECTANT, BY COUNTRY, 2021 & 2031 ($THOUSAND)
FIGURE 25.COMPARATIVE ANALYSIS OF POVIDONE IODINE MARKET FOR OTHER END USE INDUSTRY, BY COUNTRY, 2021 & 2031 ($THOUSAND)
FIGURE 26.POVIDONE IODINE MARKET, BY REGION, 2022–2031 ($THOUSAND)
FIGURE 27.U.S. POVIDONE IODINE MARKET REVENUE, 2021-2031($THOUSAND)
FIGURE 28.CANADA POVIDONE IODINE MARKET REVENUE, 2021-2031($THOUSAND)
FIGURE 29.MEXICO POVIDONE IODINE MARKET REVENUE, 2021-2031($THOUSAND)
FIGURE 30.GERMANY POVIDONE IODINE MARKET REVENUE, 2021-2031($THOUSAND)
FIGURE 31.FRANCE POVIDONE IODINE MARKET REVENUE, 2021-2031($THOUSAND)
FIGURE 32.BELGIUM POVIDONE IODINE MARKET REVENUE, 2021-2031($THOUSAND)
FIGURE 33.ITALY POVIDONE IODINE MARKET REVENUE, 2021-2031($THOUSAND)
FIGURE 34.NETHERLANDS POVIDONE IODINE MARKET REVENUE, 2021-2031($THOUSAND)
FIGURE 35.REST OF EUROPE POVIDONE IODINE MARKET REVENUE, 2021-2031($THOUSAND)
FIGURE 36.CHINA POVIDONE IODINE MARKET REVENUE, 2021-2031($THOUSAND)
FIGURE 37.JAPAN POVIDONE IODINE MARKET REVENUE, 2021-2031($THOUSAND)
FIGURE 38.INDIA POVIDONE IODINE MARKET REVENUE, 2021-2031($THOUSAND)
FIGURE 39.SOUTH KOREA POVIDONE IODINE MARKET REVENUE, 2021-2031($THOUSAND)
FIGURE 40.AUSTRALIA POVIDONE IODINE MARKET REVENUE, 2021-2031($THOUSAND)
FIGURE 41.REST OF ASIA-PACIFIC POVIDONE IODINE MARKET REVENUE, 2021-2031($THOUSAND)
FIGURE 42.BRAZIL POVIDONE IODINE MARKET REVENUE, 2021-2031($THOUSAND)
FIGURE 43.UAE POVIDONE IODINE MARKET REVENUE, 2021-2031($THOUSAND)
FIGURE 44.SAUDI ARABIA POVIDONE IODINE MARKET REVENUE, 2021-2031($THOUSAND)
FIGURE 45.SOUTH AFRICA POVIDONE IODINE MARKET REVENUE, 2021-2031($THOUSAND)
FIGURE 46.REST OF LAMEA POVIDONE IODINE MARKET REVENUE, 2021-2031($THOUSAND)
FIGURE 47.MARKET PLAYER POSITIONING, 2021
FIGURE 48.TOP WINNING STRATEGIES, BY YEAR, 2020–2021
FIGURE 49.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020–2021 (%)
FIGURE 50.TOP WINNING STRATEGIES, BY COMPANY, 2020–2021
FIGURE 51.PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 52.COMPETITIVE HEATMAP OF KEY PLAYERS
FIGURE 53.BASF SE: NET SALES, 2018–2020 ($MILLION)
FIGURE 54.BASF SE: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 55.BASF SE: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 56.LASA: NET SALES, 2018–2020 ($MILLION)
FIGURE 57.NIPPON SHOKUBAI: NET SALES, 2019–2021 ($MILLION)
FIGURE 58.NIPPON SHOKUBAI: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 59.NIPPON SHOKUBAI: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 60.SAMRAT: NET SALES, 2018–2020 ($MILLION)
FIGURE 61.3M:NET SALES, 2019–2021 ($MILLION)
FIGURE 62.3M: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 63.3M: REVENUE SHARE BY REGION, 2021(%)